Nichia Corporation v Arrow Electronics Australia Pty Ltd

Link copied
Case Copied 58 min read

FEDERAL COURT OF AUSTRALIA

Nichia Corporation v Arrow Electronics Australia Pty Ltd [2015] FCA 699

Citation: Nichia Corporation v Arrow Electronics Australia Pty Ltd [2015] FCA 699
Parties:

NICHIA CORPORATION v ARROW ELECTRONICS AUSTRALIA PTY LTD ACN 065 151 626;

ARROW ELECTRONICS AUSTRALIA PTY LTD ACN 065 151 626 v NICHIA CORPORATION
File number(s): NSD 558 of 2014
Judge(s): YATES J
Date of judgment: 10 July 2015
Catchwords:

PATENTS – standard patent for a light emitting device and display device – determination of priority date of claims in suit – whether claims in suit define more than one form of the invention – whether claims in suit fairly based on matter disclosed in priority documents

PRACTICE AND PROCEDURE – determination of separate question

Legislation: Evidence Act 1995 (Cth) s 136
Federal Court Rules 2011 r 30.01
Patents Act 1949 (UK)
Patents Act 1952 (Cth)
Patents Act 1977 (UK) s 125
Patents Act 1990 (Cth) s 43
Patents Regulations 1991 (Cth) reg 3.12
Cases cited:

Anderson’s Application [1966] FSR 218
AstraZeneca AB v Apotex Pty Ltd (2014) 226 FCR 324
Farbenfabriken Bayer AG’s Patent [1966] RPC 278
Hallen Company v Brabantia (UK) Ltd [1990] FSR 134
Leonardis v Sartas No 1 Pty Ltd (1996) 67 FCR 126
Lockwood Security Products Pty Limited v Doric Products Pty Limited (2004) 217 CLR 274
Merck & Company (Macek’s) Patent [1967] RPC 157
Thornhill’s Application [1962] RPC 199
Vehicle Monitoring Systems Pty Ltd v Sarb Management Group Pty Ltd (t/as Database Consultants Australia) (No 2) (2013) 101 IPR 496

Miller R, Burkill G, Birss C and Campbell D, Terrell on the Law of Patents (17th ed, Sweet and Maxwell, 2011)

Date of hearing: 15, 19 and 25 June 2015
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 164
Counsel for the Applicant/Cross-Respondent:

Mr SCG Burley SC with Ms CL Cochrane and Mr B Mee

Solicitor for the Applicant/Cross-Respondent:

Allens

Counsel for the Respondent/Cross-Claimant:

Mr RJ Webb SC with Mr HPT Bevan

Solicitor for the Respondent/Cross-Claimant:

Norton Rose Fulbright Australia


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 558 of 2014

BETWEEN:

NICHIA CORPORATION
Applicant

AND:

ARROW ELECTRONICS AUSTRALIA PTY LTD ACN 065 151 626
Respondent

AND BETWEEN:

ARROW ELECTRONICS AUSTRALIA PTY LTD ACN 065 151 626
Cross-Claimant

AND: NICHIA CORPORATION
Cross-Respondent

JUDGE:

YATES J

DATE OF ORDER:

10 JULY 2015

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The parties are to bring in draft orders giving effect to these reasons by 4.00 pm on 17 July 2015. 

2.If the parties cannot agree on the question of costs, the respondent is to provide a draft of the order it seeks in that regard, supported by written submissions not exceeding three pages. 

3.Any question of costs is to be determined on the papers.

Note:    Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 558 of 2014

BETWEEN:

NICHIA…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Nichia Corporation v Arrow Electronics Australia Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCA 699
Decision Date

CaseChat Overview and Summary

Nichia Corporation initiated proceedings against Arrow Electronics Australia Pty Ltd in the Federal Court of Australia, focusing on the determination of the priority date of claims related to a standard patent for a light emitting device and display device. The dispute centred on whether the claims in the suit defined more than one form of the invention and if they were fairly based on the matter disclosed in the priority documents. The primary issue before the court was the interpretation of the notation (Al,Ga)5 in the claims of the priority documents, specifically whether it required both elements to be present in the phosphor or if the presence of either element was sufficient.

The court examined the expert evidence provided by Dr Bretschneider, an expert in the field of phosphors, who opined that the notation (Al,Ga)5 indicated a phosphor that must contain both Al and Ga. However, the court found that the notation, when read as the applicant contended, covered all possible crystal combinations in the general formula of the claims, including those where only Al or Ga was present. The court further concluded that the invention as claimed was fairly based on the disclosure in the priority documents, with the priority date being 29 July 1996.

The court held that the claims in question defined more than one form of the invention, as understood under section 43(3) of the Patents Act. It rejected the respondent's version of the rewritten claim 3, finding that the priority dates of the forms defined by the claims were those identified by the applicant. The court ordered the parties to prepare draft orders to give effect to its reasons and to address the question of costs if necessary. The further case management hearing was to be scheduled shortly.

Orders

Orders of the court

1. The parties are to bring in draft orders giving effect to these reasons by 4.00 pm on 17 July 2015.

2. If the parties cannot agree on the question of costs, the respondent is to provide a draft of the order it seeks in that regard, supported by written submissions not exceeding three pages.

3. Any question of costs is to be determined on the papers.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

JP585 provides a number of non-limiting examples of the invention. Example 1 discloses a phosphor having the composition (Y1.2Gd0.8)5Al3O12:Ce. This notation indicates that the phosphor does not contain Ga. However, I note, for later consideration, that Example 1 refers to the use of aluminium oxide and gallium oxide in the preparation of the phosphor. Example 2 discloses a phosphor made in the same way as the phosphor of Example 1, except that the content of Gd has been increased. Example 3 similarly discloses a phosphor made in the same way as the phosphor of Example 1, except that Sm has been added. JP585 describes this phosphor as (Y0.39Gd0.57Ce0.03Sm0.01)3Al5O12. Once again, this notation indicates that the phosphor does not contain Ga.The expert evidenceDr Bretschneider Dr Bretschneider is an expert retained by the respondent’s solicitors in this proceeding. Dr Bretschneider was asked by the respondent’s solicitors to provide an opinion on a number of matters, including what he understood to be identified by the notation (Al,Ga)5 in claim 1 of JP585. Dr Bretschneider made an affidavit on 1 June 2015, which was read at the hearing, save for some passages. Dr Bretschneider expressed his understanding that this notation indicates a phosphor that contains both Al and Ga. He explained his understanding in the following way. Dr Bretschneider said that, before 29 July 1996, he was aware of the use of equivalent notations in the field of chemistry associated with geology and mineralogy, where the notation indicated that a material contained both elements in respective amounts that had not been, or could not be, quantified. In relation to phosphors, he said that he was aware of formulas where, absent a direct indication that an element was not present, the notation indicated that the phosphor material contained each element. In relation to some semiconductor materials, he said that the usage of “the comma notation” was less common. He said, however, that, in the semiconductor industry, comma notations are sometimes used to denote a class of semiconductors where the exact ratio of the constituent elements was determined by the targeted emission wavelength. In his affidavit, Dr Bretschneider made clear that his understanding of these matters was based on his knowledge and experience acquired before 29 July 1996. He went on, however, to justify his opinion on the meaning of (Al,Ga)5 as used in claim 1 of JP585 by reference to other information, including formulas published in the literature arising from research conducted before July 1996 in which garnet phosphors containing Y and Al, and potentially also Ga, activated with Ce had been studied. In this connection, Dr Bretschneider annexed a number of publications, including articles by Blasse and Bril who conducted work in the Philips Research Laboratories at N.V. Philips Gloeilampenfabrieken at Eindhoven in The Netherlands. The purpose of referring to these articles was twofold. First, the authors employed the notation (Al,Ga)5 when describing particular Ce-activated phosphors. One article (Blasse G and Bril A, “Investigation of Some Ce3+-Activated Phosphors” (1967) 47 The Journal of Chemical Physics 5139-5145) (Blasse and Bril), refers to studies on a system described as Y3(Al,Ga)5O12–Ce (this is the same as Y3(Al,Ga)5O12:Ce). Dr Bretschneider said that this is a material represented by the phosphor formula of claim 1 in JP585 where RE is Y. I note, however, that, when describing the system, Blasse and Bril use that particular notation to describe phosphors where Al is present and Ga is not present, as well as phosphors where Ga is present and Al is not present. I do not see, therefore, how Blasse and Bril assists the respondent’s case, based on Dr Bretschneider’s opinion, that the notation (Al,Ga)5 in claim 1 of JP585 denotes phosphors in which both Al and Ga must be present—assuming, in any event, that one can properly use the information in Blasse and Bril to determine the meaning of the notation (Al,Ga)5 used in JP585.

Decision

Reasons for decision

When the notation (Al,Ga)5 as used in claim 1 of JP585 is read in the way that the applicant contends, as I think it must, the evidence establishes that there is no crystal combination in the general formula in claim 3 of the 355 specification that is not covered by the formula in claim 1 of JP585. CONCLUSION For these reasons, I accept that there is a real and reasonably clear disclosure in JP585 of the forms of the invention defined by the general formula in claim 3 of the 355 specification. I am satisfied that the invention as claimed in claim 3 of the 355 specification is fairly based on matter disclosed in JP585 and that the priority date of the claim is 29 July 1996. I record for completeness that the respondent advanced an alternative priority date for claim 3 of the 355 specification (27 December 1996) based on disclosures in another priority document, Japanese patent application JP8-359004. Having regard to the conclusion I have reached, it is not necessary for me to consider that alternative. Further, as I have noted, the respondent accepts that if, as I have found, claim 1 of the 355 specification defines more than one form of the invention, then the priority dates of those forms are the dates identified by the applicant. DISPOSITION The parties are to bring in draft orders to give effect to these reasons. The applicant has already provided written submissions on the question of costs. If, after consideration of these reasons, the respondent disputes the applicant’s entitlement to costs as sought, the respondent is to provide a draft of the order it seeks in that regard, supported by written submissions not exceeding three pages. I will determine that question on the papers. The draft orders should also provide for the appointment of a further case management hearing in the near future.

Ratio Decidendi

Legal Principle Established

Therefore, I reject the respondent’s case to the extent that it rests on its version of claim 3 rewritten to take account of the claim’s dependency on claim 1.Consideration In AstraZeneca, the Full Court emphasised the terms in which the claim is drafted and directed attention to whether the claim, according to its terms, allows for alternatives. Claim 1 and claim 3 of the 355 specification are cast in terms that are different to the claim considered in AstraZeneca. Claim 1 includes two discrete and express selection steps—one referable to the selection of the “large” metal ions and the other referable to the selection of the “small” metal ions in the fluorescent material—providing for differently constituted phosphors, depending on the selections made and the combinations arrived at. Claim 3, although differently drafted, also contains discrete and express selection steps. Similarly to claim 1, there is a stated, but different, selection with respect to the “large” metal ions in the fluorescent material. The constituents of this material are also determined by the selection of a value for r from the given range. The general formula in claim 3 also provides for a selection in relation to the “small” metal ions of the fluorescent material by providing a range of values for s. These various selection steps combine to provide differently constituted phosphors. I am satisfied that, by their terms, each of claims 1 and 3 of the 355 specification envisage and provide for different forms of the invention, as understood by s 43(3) of the Act. In each case, these forms are represented by the individual phosphors obtained after the selection steps have been undertaken. THE PRIORITY DATES OF THE CLAIMSIntroduction The respondent accepts that if, as I have found, claim 1 of the 355 specification defines more than one form of the invention, then the priority dates of those forms are the dates that the applicant has identified. As I have found that claim 3 of the 355 specification also defines more than one form of the invention, the question then becomes whether the forms of the phosphor represented by the general formula in that claim are disclosed in JP585. This question focuses attention on the notation (Al,Ga)5 used in claim 1 and claim 2 of JP585, and elsewhere in JP585, where it is stated that the phosphor of the invention therein described is represented by RE3(Al,Ga)5O12:Ce, where RE is at least one selected form Y, Gd and Sm. As originally advanced, the issue that divided the parties was this: Does the notation (Al,Ga)5 as used in the general formula in claim 1 of JP585, denote any mixing of Al and Ga so as to include 100% Al and 0% Ga, and 0% Al and 100% Ga, provided the total number of atoms is conserved to make five atoms (ie, so as to include RE3Al5O12:Ce and RE3Ga5O12:Ce, respectively), as the applicant contends, or does it denote, as the respondent contends, that Al and Ga must each be present in the phosphor, provided, once again, that the total number of atoms is conserved to five atoms? JP585